2026. Characterizing Deep Quality-of-Life Response in the TRuE-V1/TRuE-V2 Studies of Ruxolitinib Cream in Nonsegmental Vitiligo. SKIN The Journal of Cutaneous Medicine. 10, 2 (Mar. 2026), s752. DOI:https://doi.org/10.25251/bpnxm492.